GDERF

Galderma Group AG

OTC· CIK 0002021390

$230.86 +10.72 (+4.87%)

Oct 23 4:00 PM ET · prev $220.14

1 year

+30.4%

from $177.05 · Oct 24

30 days

+13.4%

from $203.60

52-week range

$171.60–245.97

−6% from high · low Oct 27

Avg volume 20D

1.1K

Sep 28 spike 11.9K

Short interest

491.4K

+15.2%

Days to cover

139.6

at average volume

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

X Aug 14 Short interest jumps 43.1% to 366.3K

Signal stack

Where each data set points today.

Short sellersBUILDING

Short interest +15.2% to 491.4K shares. 139.6 days to cover.
TrendUPTREND

13% above its 50-day average.

Catalysts

Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.

Recent

May 1, 2026

Clinical Trial

To Evaluate the Efficacy and Safety of Nemolizumab for 12 Weeks in Participants With Chronic Kidney Disease With Associated Moderate to Severe Pruritus

Phase Phase 3 — COMPLETED

Mar 27, 2026

Clinical Trial

Rosacea and Ivermectin

Phase Phase 2 — COMPLETED

Earnings setup

Estimates

Revision history: 🔒 Fresh data — subscribers only

Period	EPS est.	Range	30D rev.	Revenue
Current Q	🔒 Fresh data — subscribers only
Next Q	🔒 Fresh data — subscribers only
Current FY	🔒 Fresh data — subscribers only
Next FY	🔒 Fresh data — subscribers only

Short side

FINRA· Sep 30, 2026

491,365

shares short

+15.2%

vs prior settlement

139.6

days to cover